• Management/Scientific Team
  • Board of Directors
  • Scientific Advisors

Jack V. Talley – CEO

Jack V. Talley is a pharmaceutical management professional with more than 30 years of experience in the industry. He has taken three companies successfully public. He has been responsible for more than 20 equity issuances in both the private and public sectors, raising in aggregate in excess of $100 million.  Two of the three companies he has taken public have been successfully sold, the third is still independent. He has been responsible for numerous business development transactions and has secured product approvals in both Europe and the United States for a wide variety of investigational drugs.

Most recently he was the President, CEO and a member of the Board of Directors for Alissa Pharma, LLC a privately held company focused on antibody directed isotopes for various forms of cancer. Previously he was the CEO, President and a Director of Actinium Pharmaceuticals, Inc. (API) which he took public. Mr. Talley joined API from the position of President, Chief Executive Officer and a Director at EpiCept Corporation, which he also took public. Prior to EpiCept, Mr. Talley was the Chief Executive Officer of Consensus Pharmaceuticals, Inc., a biotechnology drug discovery start-up company that developed a proprietary peptide-based combinatorial library screening process.

Prior to joining Consensus, Mr. Talley led Penwest Ltd.’s efforts in its IPO spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998 and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Penwest was eventually acquired by Endo. Mr. Talley led the alliance between Penwest and Endo. Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs.  When the company was merged with Sanofi, he launched various new pharmaceutical products and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.

William Z. Levine, DDS – Executive Chairman and Founder

Dr. Bill Levine is the founder of Izun Pharmaceuticals Corporation, a biopharmaceutical company specializing in Botanical Medicine. This area of specialty pharma develops pharmaceutical and healthcare products from plant-based sources. Bill, who received his DDS degree and specialty training in Periodontics from Columbia University, initially utilized this background to formulate novel oral care products to treat periodontal disease more effectively. Izun has also developed wound care products, oncology support products, and products targeting women’s health care.

Subsequently, recognizing the Izun expertise in botanicals, Bill applied this knowledge to the cannabis plant and established CannRx.  In a short time, CannRx has developed validated assays (receiving ISO 17025 service laboratory certification) and new and differentiated delivery systems. CannRx has identified & licensed new potent strains and appears well on its way to establishing itself as a leading player in the cannabis field.    

Elliot Hahn – Vice Chairman and Executive Director

Elliot F. Hahn, Ph.D. currently serves as Vice Chairman and Executive Director of Izun Pharmaceuticals Corporation. Dr. Hahn is also the Executive Chairman of Accu-Break Pharmaceuticals, Inc., a privately held company. He co-founded Andrx Corporation and was Chairman Emeritus and a Director of Andrx until its acquisition by Watson Pharmaceuticals, Inc. in November 2006 for $1.9 billion. He was President of Andrx from 1993 until 2003, served as Chairman of the Board from 2002-03 and as interim CEO from 2001-02. From June 1990 until February 1993, Dr. Hahn was Vice President for Scientific Affairs of IVAX, where he was involved in the evaluation and licensing of product opportunities and was responsible for maintaining IVAX’s intellectual property. Prior to that, he was Vice President of Research at the pharmaceutical subsidiary of IVAX.

Before joining IVAX, Dr. Hahn was an associate professor at The Rockefeller University, an assistant professor at Albert Einstein College of Medicine, and a member of the Institute for Steroid Research at Montefiore Hospital, all in New York City. He received a Ph.D. in Organic Chemistry from Cornell University. Dr. Hahn received a B.S. with Honors in Chemistry from the City College of New York. He has authored or co-authored over sixty peer-reviewed scientific publications.

Leslie Kraus – CFO/COO

Les Kraus commenced as CFO/COO of Izun in 2013. For the 12 years prior to this, Les served as Chief Financial Officer of Retail Apparel Group Pty Ltd (RAG), the largest menswear retailer in Australia. During his time at RAG, Les managed two sale processes to private equity firms. He is a qualified Chartered Accountant in Australia and has over 30 years of operational and financial experience within the clothing industry, covering both retail and wholesale businesses.

Gabriel Nussbaum, MD, PhD – Director of Scientific Affairs

Gabe joined the Izun team in 2004 and continues to be instrumental in the development of Izun’s products. A basic science researcher and clinician, Gabe is a US board-certified physician for internal medicine and has performed graduate studies and post-doctoral research in inflammation at the Weizmann Institute of Science, an international center of scientific research in Rehovot, Israel. Dr. Nussbaum has numerous publications.

Amy Rosenbluh, PhD – Director of Production, Laboratory Director

Amy joined Izun in 2006, initially as Director of the R&D and QC Laboratory, and has since added Director of Production to her responsibilities. Amy obtained her Master’s degree from Harvard University and her Ph.D. from Tel Aviv University in Israel, with post-doctoral fellowships at both Stanford University and the Weizmann Institute of Science in Rehovot, Israel.

Amy brings to Izun rich experience in academic research and in managerial positions, both in academia and in the private sector. Dr. Rosenbluh holds a patent and has published a chapter in a book as well as numerous articles.

William Z. Levine – Chairman

Dr. Bill Levine is the founder of Izun Pharmaceuticals Corporation, a biopharmaceutical company specializing in Botanical Medicine. This area of specialty pharma develops pharmaceutical and healthcare products from plant-based sources. Bill, who received his DDS degree and specialty training in Periodontics from Columbia University, initially utilized this background to formulate novel oral care products to treat periodontal disease more effectively. Izun has also developed wound care products, oncology support products, and products targeting women’s health care.

Subsequently, recognizing the Izun expertise in botanicals, Bill applied this knowledge to the cannabis plant and established CannRx.  In a short time, CannRx has developed validated assays (receiving ISO 17025 service laboratory certification) and new and differentiated delivery systems. CannRx has identified & licensed new potent strains and appears well on its way to establishing itself as a leading player in the cannabis field.        

Jack Talley – CEO

Jack V. Talley is a pharmaceutical management professional with more than 30 years of experience in the industry. He has taken three companies successfully public. He has been responsible for more than 20 equity issuances in both the private and public sectors, raising in aggregate in excess of $100 million.  Two of the three companies he has taken public have been successfully sold, the third is still independent. He has been responsible for numerous business development transactions and has secured product approvals in both Europe and the United States for a wide variety of investigational drugs.

Most recently he was the President, CEO and a member of the Board of Directors for Alissa Pharma, LLC a privately held company focused on antibody directed isotopes for various forms of cancer. Previously he was the CEO, President and a Director of Actinium Pharmaceuticals, Inc. (API) which he took public. Mr. Talley joined API from the position of President, Chief Executive Officer and a Director at EpiCept Corporation, which he also took public. Prior to EpiCept, Mr. Talley was the Chief Executive Officer of Consensus Pharmaceuticals, Inc., a biotechnology drug discovery start-up company that developed a proprietary peptide-based combinatorial library screening process.

Prior to joining Consensus, Mr. Talley led Penwest Ltd.’s efforts in its IPO spin-off of its subsidiary Penwest Pharmaceuticals Co. in 1998 and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Penwest was eventually acquired by Endo. Mr. Talley led the alliance between Penwest and Endo. Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs.  When the company was merged with Sanofi, he launched various new pharmaceutical products and participated in the 1988 acquisition of Sterling Drug by Eastman Kodak Co. Mr. Talley received his B.S. in Chemistry from the University of Connecticut and completed coursework towards an M.B.A. in Marketing from New York University, Graduate School of Business.

Elliot Hahn – Vice Chairman and Executive Director

Elliot F. Hahn, Ph.D. currently serves as Vice Chairman and Executive Director of Izun Pharmaceuticals Corporation. Dr. Hahn is also the Executive Chairman of Accu-Break Pharmaceuticals, Inc., a privately held company. He co-founded Andrx Corporation and was Chairman Emeritus and a Director of Andrx until its acquisition by Watson Pharmaceuticals, Inc. in November 2006 for $1.9 billion. He was President of Andrx from 1993 until 2003, served as Chairman of the Board from 2002-03 and as interim CEO from 2001-02. From June 1990 until February 1993, Dr. Hahn was Vice President for Scientific Affairs of IVAX, where he was involved in the evaluation and licensing of product opportunities and was responsible for maintaining IVAX’s intellectual property. Prior to that, he was Vice President of Research at the pharmaceutical subsidiary of IVAX.

Before joining IVAX, Dr. Hahn was an associate professor at The Rockefeller University, an assistant professor at Albert Einstein College of Medicine, and a member of the Institute for Steroid Research at Montefiore Hospital, all in New York City. He received a Ph.D. in Organic Chemistry from Cornell University. Dr. Hahn received a B.S. with Honors in Chemistry from the City College of New York. He has authored or co-authored over sixty peer-reviewed scientific publications.

Oscar Schafer

Mr. Schafer is the Chairman of Rivulet Capital, LLC, a private investment partner, which he seeded in 2012.

Prior to Rivulet, Mr. Schafer founded O.S.S. Capital Management in 2001. Between 1982 and 2001, he was a member of Cumberland Associates. Prior to that, Mr. Schafer was a General Partner at Steinhardt, Fine, Berkowitz,  & Co. from 1970 to 1982.  He began his investment career with positions at Kuhn, Loeb & Co., Havenfield Corp., and Boxwood Associates between 1964 and 1970.  He has been a member of the Barron’s Roundtable for 30 years.

Mr. Schafer earned a BA, Magna Cum Laude, at Harvard College in 1961 and an MBA at Harvard Business School in 1964.

He has served on The Visiting Committee for the Department of Music at Harvard and he funds The Oscar Straus Schafer Fellowship for teachers of Harvard’s introductory music course.  He currently serves on the board of the Schafer Family Foundation, which supports the arts and social service organizations, and on the Board of Trustees at New York Presbyterian Hospital.  Mr. Schafer joined the board of The NY Philharmonic Orchestra in 2007 and became its Chairman in January 2015.

Mr. Schafer is married to Didi Fenton-Schafer, who serves on the Board of the Central Park Conservancy and is Vice Chairman of the New York Common Pantry.  The couple are special event donors and were underwriters of the New York Philharmonic’s 9/11 Tenth Anniversary Concert. Since the summer of 2007, Mr. & Mrs. Schafer have presented the Philharmonic’s annual Concerts in the Parks and, as a tribute to his wife, Mr. Schafer conducted the orchestra in Central Park in July 2013.

Hersh Cooper

Hersh Cooper graduated from Melbourne University in Australia with Bachelor of Laws (Hons) and Bachelor of Commerce degrees in 1973. He practiced as an Attorney until 1997, specializing in Taxation and Mergers and Acquisitions. He served as director and/or Chairman of several listed public companies. Since moving to Israel in 1997, he has been active in the property development sector as well as acting as legal Counsel for several Australian companies operating in Israel. In addition to serving on the Board of Izun, he holds a Board position at FIBI Holdings Ltd., the publicly listed holding company of the First International Bank of Israel and several charities.

 

Professor Ben Corn, MD

  • Director of Institute of Radiation Oncology
  • Sourasky Medical Center, Tel Aviv
  • Key opinion leader and international speaker in all aspects of radiation oncology

Stephen T. Sonis, DMD, DMSc

  • Chair of Oral Medicine, Infection and Immunity
  • Harvard Dental School and Dana Farber Cancer Institute
  • Leading world expert in ulcerative mucosal diseases

David Steed, MD, FACS

  • Director, Wound Healing/Limb Preservation Program
  • University of Pittsburgh
  • Vascular Surgeon, Specialist in chronic wounds

Ray C. Williams, DMD

  • Dean, School of Dental Medicine
  • Stony Brook University School
  • Internationally known researcher and educator in dental medicine and leading KOL